Recursion Pharmaceuticals ( RXRX +1.27%) has been a pioneer in using artificial intelligence (AI) to improve the drug ...

Recursion CEO Chris Gibson is out after 12 years as the ambitious "techbio" company positions itself for its next phase of AI drug discovery.

AI-based drug developer Recursion’s stock barely moved Wednesday, then dropped Thursday and Friday, after reporting mixed third quarter results, setting the stage for future pipeline announcements—and ...

Recursion Pharmaceuticals has designated its top research executive, Najat Khan, to succeed co-founder Chris Gibson as president and chief executive of the clinical-stage biotechnology company, ...

Altitude Lab Fund will provide pre-seed funding for early-stage startups affected by changes to grant programs administered by the National Institutes of Health. Accepted applicants will be admitted ...

Recursion Pharmaceuticals, a drug discovery company that applies artificial intelligence to biology, is shoring up its technology platform by buying two startups that bolster its chemistry ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), a $2.48 billion market cap biotech company, saw Chief Executive Officer Christopher Gibson sell 617,875 shares of Class A Common Stock on August 11, 2025 ...